Sonendo AI Stock Analysis
Want to see SONX full AI Analyst Report?
Sonendo (SONX) AI Stock Analysis
Sonendo
(Other OTC:SONX)
The score is held down primarily by weak financial quality—shrinking revenue, ongoing losses/negative cash flow, and especially negative equity—paired with bearish technicals (price below major moving averages with negative MACD). Improvements in loss and cash burn provide some support, but valuation metrics offer limited reassurance due to negative earnings and no stated dividend.
Sonendo (SONX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $547.07K
- Dividend Yield
- ―
- Average Volume (3M)
- 776
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.32
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 130
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Sonendo Business Overview & Revenue Model
Company Description
Sonendo, Inc. operates as a commercial-stage medical technology firm, dedicated to innovating, producing, and marketing advanced devices for root canal treatment across the United States and Canada. A flagship offering is GentleWave, an innovative de...
How the Company Makes Money
Sonendo generates revenue primarily by selling its GentleWave System and recurring consumables used with each procedure. A key revenue stream is the sale (and/or placement) of the GentleWave console/capital equipment to dental practices and clinics....
Sonendo Earnings Call Summary
The earnings call for Sonendo reflects a positive sentiment overall, with significant improvements in gross margins, operating expenses, and adjusted EBITDA loss, despite challenges in PI sales and total revenue decline. The company is optimistic about its strategic reset and future growth prospects.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Sonendo Q2 2024 earnings call, the company provided updated guidance and highlighted several key metrics illustrating their progress. Sonendo raised their full-year 2024 revenue guidance to a range of $31 million to $32 million, up from the previous $29 million to $31 million. They reported a significant improvement in gross margins, with adjusted gross margin increasing to 40.7% in Q2 2024 from 28.7% in the prior year quarter. The company also achieved a 53% reduction in year-over-year adjusted EBITDA loss, reporting a loss of $5.7 million for the quarter. Sonendo's strategic reset focused on commercial execution, gross margin expansion, and cash conservation, with a notable 42% reduction in operating expenses compared to the prior year. Despite a decrease in PI sales by 15% year-over-year, the company emphasized stabilizing utilization rates and anticipates low single-digit growth in PI sales for the second half of the year. Additionally, Sonendo aims to achieve adjusted gross margins in the 40% to 41% range for the latter half of 2024, with long-term aspirations of reaching 60% as they continue to enhance their operational and financial performance.
Sonendo Financial Statement Overview
Summary
Financials remain high risk: revenue is contracting (2025: -9.9% y/y) and profitability/cash flow are still negative. Offsetting this, losses and operating cash burn have narrowed materially versus prior years, indicating improving cost control, but negative stockholders’ equity in 2025 is a major weakness that limits flexibility.
Income Statement
32NegativeBalance Sheet
18Very NegativeCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.70M | 28.55M | 31.70M | 43.87M | 41.66M | 33.20M |
| Gross Profit | 11.84M | 11.97M | 11.84M | 10.72M | 10.48M | 8.34M |
| EBITDA | -27.36M | -12.62M | -26.61M | -54.77M | -51.00M | -41.29M |
| Net Income | -28.03M | -14.41M | -28.03M | -60.92M | -57.05M | -48.50M |
Balance Sheet | ||||||
| Total Assets | 31.27M | 18.84M | 31.27M | 78.16M | 137.28M | 115.50M |
| Cash, Cash Equivalents and Short-Term Investments | 11.63M | 5.01M | 11.63M | 46.78M | 91.45M | 84.64M |
| Total Debt | 18.93M | 16.16M | 18.93M | 40.35M | 38.99M | 29.33M |
| Total Liabilities | 26.07M | 21.15M | 26.07M | 49.74M | 55.33M | 43.44M |
| Stockholders Equity | 5.19M | -2.32M | 5.19M | 28.42M | 81.95M | 72.06M |
Cash Flow | ||||||
| Free Cash Flow | -24.81M | -11.02M | -24.81M | -46.99M | -62.43M | -50.58M |
| Operating Cash Flow | -24.65M | -11.02M | -24.65M | -46.06M | -61.07M | -48.60M |
| Investing Cash Flow | 45.81M | 2.40M | 45.81M | 42.40M | -74.43M | -1.97M |
| Financing Cash Flow | -24.95M | 3.41M | -24.95M | 4,000 | 68.53M | 83.50M |
Sonendo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONX, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.22, and below the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 12.67 is Positive, neither overbought nor oversold. The STOCH value of -0.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SONX.
Sonendo Risk Analysis
Sonendo disclosed 85 risk factors in its most recent earnings report. Sonendo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSonendo Peers Comparison
Overall Rating
COCH53Neutral
ECOR44Neutral
MOVE44Neutral
LFWD42Neutral
PAVM42Neutral- SONX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| COCH | 53Neutral | $53.56M | -1.86 | -9999.00% | ― | 11.06% | 64.70% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ECOR | 44Neutral | $71.22M | -5.39 | 498.83% | ― | 27.26% | 20.47% |
| MOVE | 44Neutral | $156.50M | -0.47 | -9.67% | ― | 843.62% | 21.98% |
| LFWD | 42Neutral | $16.55M | -0.34 | -310.86% | ― | -10.68% | 55.33% |
| PAVM | 42Neutral | $12.47M | -0.10 | -33.51% | ― | -89.02% | -107.75% |
| SONX | 41Neutral | $158.87K | -0.42 | -1003.06% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SONX | Sonendo Inc | 0.37 | 0.11 | 42.69% | |
| LFWD | Lifeward Ltd. | 5.76 | -0.49 | -7.80% | |
| ECOR | Electrocore | 7.71 | 2.00 | 35.03% | |
| PAVM | Pavmed | 1.60 | -9.00 | -84.87% | |
| MOVE | Corvex, Inc. | 5.70 | -1.85 | -24.47% | |
| COCH | Envoy Medical, Inc. Class A | 6.95 | 0.31 | 4.62% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026